Medication info
Vildatin Tablet 50mg (Vildagliptin)

Vildatin Tablet 50mg (Vildagliptin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
Ahn-Guk New Pharm Co., Ltd.
Appearance
White to light yellow round tablets
Packaging
30 tablets/box [(10 tablets/Alu-Alu x 3)]
Approval status
Active

MFDS item code 201908042 · Approved 2019.11.22 · Insurance code 053601510

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For monotherapy or when used in combination with metformin in patients with no previous experience of antidiabetic drug treatment, administer 50mg once daily in the morning, or 100mg daily as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with metformin or thiazolidinedione monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg daily, as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient population, once-daily vildagliptin 100mg was not more effective than once-daily 50mg. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is used in combination (as triple therapy) is 100mg daily, as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is used in combination is 100mg daily, as 50mg twice daily, in the morning and evening. This medicine may be taken with or without food, and doses greater than 100mg daily are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember and take the next dose at your usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment: This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Patients with moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 2) under “3. General precautions” in the Precautions for Use)

Ingredients

Manufacturer
Ahn-Guk New Pharm Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to assist in the control of blood sugar levels in patients with type 2 diabetes. It can be administered alone or in combination with meal therapy and exercise. If there has been no prior treatment with diabetes medications or if blood sugar control is not achievable with monotherapy, this medication may be combined with Metformin. If sufficient effectiveness is not achieved with monotherapy using sulfonylureas, Metformin, or thiazolidinediones, this medication is used in combination. If blood sugar control remains challenging after combination therapy with sulfonylureas and Metformin, this medication may also be administered. Additionally, it improves blood sugar control in cases where insulin alone or in combination with Metformin is insufficient.

How to take

Adult dose

For monotherapy or when used in combination with metformin in patients with no previous experience of antidiabetic drug treatment, administer 50mg once daily in the morning, or 100mg daily as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with metformin or thiazolidinedione monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg daily, as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient population, once-daily vildagliptin 100mg was not more effective than once-daily 50mg. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is used in combination (as triple therapy) is 100mg daily, as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is used in combination is 100mg daily, as 50mg twice daily, in the morning and evening. This medicine may be taken with or without food, and doses greater than 100mg daily are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember and take the next dose at your usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment: This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Patients with moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 2) under “3. General precautions” in the Precautions for Use)

Precautions

This medication should not be administered to certain patients. Individuals allergic to the active ingredient or other components, as well as patients with type 1 diabetes or diabetic ketoacidosis, should not use it. Moreover, it contains lactose and should not be given to patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. While taking this medication, hepatic abnormalities may occur infrequently, so it is important to have regular liver function tests before and during administration. If there is a significant increase in liver enzyme levels or symptoms of jaundice appear, the use of this medication should be discontinued immediately. Additionally, this medication does not substitute for insulin in patients with type 1 diabetes or those who necessarily require insulin, so insulin treatment is not sufficient if needed alone. Taking this medication in conjunction with insulin secretagogues like sulfonylureas may increase the risk of hypoglycemia, so it is important to be vigilant for symptoms of low blood sugar. If symptoms of hypoglycemia develop, it is essential to consult with healthcare professionals immediately. Neurological symptoms such as dizziness or headache may occur, so it is advisable to avoid driving or operating machinery if such symptoms arise. If severe abdominal pain or vomiting occurs, which are symptoms of acute pancreatitis, discontinue use immediately and visit a hospital. If abnormal symptoms such as blisters, ulcers, or rashes appear on the skin, inform a doctor immediately and seek appropriate care. Particular attention is needed as skin conditions such as bullous pemphigoid have been reported. Women who are pregnant or nursing should not use this medication, and it is not recommended for children and adolescents under 18 years as safety and efficacy have not been established. In case of overdose, there is no specific antidote, and supportive care will be provided according to symptoms. This medication cannot be removed via hemodialysis. Keep out of reach of children and do not transfer to another container for safety.

Side effects

  • Hepatitis
  • impaired liver function
  • increased transaminase levels
  • vascular edema
  • tremors
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
Show 75 more
  • pharyngitis
  • asthenia
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood glucose
  • sweating
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and disabling arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • upper respiratory infection
  • acute myocardial infarction
  • nodular arrhythmia
  • acute cholecystitis
  • pneumothorax
  • cholelithiasis
  • femoral fracture
  • peripheral artery occlusive disease
  • supraventricular tachycardia
  • congestive heart failure
  • gastric ulcer
  • gastric cancer
  • increased INR
  • appendicitis
  • pulmonary edema
  • vertigo
  • chest discomfort
  • dyspnea
  • cough
  • dyspepsia
  • drowsiness
  • pruritus
  • dry mouth
  • vomiting
  • insomnia
  • renal impairment
  • lip blisters
  • hunger
  • sensory impairment
  • spinal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • angina
  • heart failure
  • cardiomegaly
  • cardiac arrest
  • renal cyst
  • lung carcinoma
  • leg pain
  • increased C-reactive protein
  • bullous pemphigoid
  • myalgia
  • paresthesia
  • fever
  • edema
  • increased creatine phosphokinase
  • elevated AST
  • elevated C-reactive protein
  • increased myoglobin levels
  • arthralgia
  • skin lesions
  • loose stools
  • mucous stools
  • bloody stools

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and should be kept at a cool temperature below 30°C. This will help maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

White to light yellow round tablets

Package unit

30 tablets/box [(10 tablets/Alu-Alu x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.